These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 7377217)
1. Implications of the Lannett and Pharmadyne decisions. Vetrano AJ Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217 [TBL] [Abstract][Full Text] [Related]
2. Update on the Lannett and Pharmadyne decisions. Vetrano AJ Am J Hosp Pharm; 1981 Feb; 38(2):222-3. PubMed ID: 7211886 [TBL] [Abstract][Full Text] [Related]
6. FDA takes action against firms in scandal over generic products. Pollner F Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736 [No Abstract] [Full Text] [Related]
7. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984. Hogan GF Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238 [TBL] [Abstract][Full Text] [Related]
8. A strike against preemption. Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422 [TBL] [Abstract][Full Text] [Related]
9. Look-alike drugs and unfair competition. An update of Inwood Laboratories v. Ives Laboratories. Shapiro LJ Am Pharm; 1985 Oct; NS25(10):49-50. PubMed ID: 4061279 [No Abstract] [Full Text] [Related]
10. Keeping prescription drugs safe and effective. Bryan PA Am Fam Physician; 1974 Nov; 10(5):189-93. PubMed ID: 4421343 [No Abstract] [Full Text] [Related]
11. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
12. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs. Patsner B Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473 [No Abstract] [Full Text] [Related]
13. Use of generics will mean cost savings. Nelson G Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132 [No Abstract] [Full Text] [Related]
14. The impact of Wyeth v. Levine on FDA regulation of prescription drugs. Ausness RC Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542 [TBL] [Abstract][Full Text] [Related]
15. FDA user fees and innovation. Somberg J Am J Ther; 2008; 15(2):97. PubMed ID: 18356626 [No Abstract] [Full Text] [Related]
16. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
17. Pharmacy inspections: constitutional without a warrant? Simonsmeier LM Am J Hosp Pharm; 1979 Jan; 36(1):85-8. PubMed ID: 758791 [TBL] [Abstract][Full Text] [Related]
18. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
19. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification. Mattia A; Merker R Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714 [TBL] [Abstract][Full Text] [Related]